Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus cisplatin/5-fluorouracil neoadjuvant chemotherapy followed by cisplatin-IMRT in locally advanced nasopharyngeal carcinoma
ChiCTR-OIC-16008201Phase 2Recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Started Feb 2015; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-OIC-16008201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008201.